Biomarkers in Urine Samples From Patients With Wilms Tumor

Children's Oncology Group

Status: Completed

Conditions: Kidney Cancer

Treatments: Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: proteomic profiling; Other: medical chart review

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01550393

AREN12B4 (Other Identifier)

NCI-2012-00702 (Registry Identifier)

CDR0000727337 (Other Identifier)

COG-AREN12B4 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.

Full description

OBJECTIVES:

• To validate the prognostic performance of specific-candidate Wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs) in urine specimens collected at diagnosis from 50 patients with favorable histology Wilms tumor who relapsed and 50 patients who did not relapse.

OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.

Enrollment: 100 estimated patients

Sex: All

Ages: Under 120 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Urine specimens collected at diagnosis will be selected from patients with stage II-III Wilms tumors, with both local and non-local sites of disease relapse
• Clinical patient information (urinalysis/macro, age, gender, congenital defects/syndromes, comorbidities, tumor stage, size, pathology, therapy, outcome) available

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified